Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 13, Number 1—January 2007

Research

Model for Assessing Human Papillomavirus Vaccination Strategies

Elamin H. Elbasha*Comments to Author , Erik J. Dasbach*, and Ralph P. Insinga*
Author affiliations: *Merck Research Laboratories, North Wales, Pennsylvania, USA;

Main Article

Figure 6

Sensitivity analysis. A) Incidence of genital warts due to human papillomavirus (HPV) 6/11 infection among boys and men >12 years of age, by strategy, 10 years’ duration of protection. B) Incidence of genital warts due to (HPV 6/11 infection among girls and women >12 years of age by strategy, 10 years’ duration of protection.

Figure 6. Sensitivity analysis. A) Incidence of genital warts due to human papillomavirus (HPV) 6/11 infection among boys and men >12 years of age, by strategy, 10 years’ duration of protection. B) Incidence of genital warts due to (HPV 6/11 infection among girls and women >12 years of age by strategy, 10 years’ duration of protection.

Main Article

TOP